These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 30866688)
1. Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice. Kang HJ; Kim J; Cho SH; Park SJ; Yoo HS; Kang IC Integr Cancer Ther; 2019; 18():1534735419830765. PubMed ID: 30866688 [TBL] [Abstract][Full Text] [Related]
2. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells. Lee Y; Wang Y; James M; Jeong JH; You M Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929 [TBL] [Abstract][Full Text] [Related]
4. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595 [TBL] [Abstract][Full Text] [Related]
5. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways. Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044 [TBL] [Abstract][Full Text] [Related]
6. [Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells]. Kang X; Lu P; Cui Y; Wang Y; Zhang Q; Gong Y; Xu Z Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):490-6. PubMed ID: 26463323 [TBL] [Abstract][Full Text] [Related]
7. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009 [TBL] [Abstract][Full Text] [Related]
8. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644 [TBL] [Abstract][Full Text] [Related]
9. Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer. Song SY; Park JH; Park SJ; Kang IC; Yoo HS Integr Cancer Ther; 2022; 21():15347354221144311. PubMed ID: 36565160 [TBL] [Abstract][Full Text] [Related]
10. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614 [TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255 [No Abstract] [Full Text] [Related]
12. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325 [TBL] [Abstract][Full Text] [Related]
13. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021 [TBL] [Abstract][Full Text] [Related]
14. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705 [TBL] [Abstract][Full Text] [Related]
15. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241 [TBL] [Abstract][Full Text] [Related]
16. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer]. Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053 [TBL] [Abstract][Full Text] [Related]
17. Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway. Chen SF; Zhang ZY; Zhang JL Mol Med Rep; 2017 Sep; 16(3):2733-2739. PubMed ID: 28656237 [TBL] [Abstract][Full Text] [Related]
18. Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis. Nathani A; Khan I; Tanimoto MH; Mejía JAA; DE Miranda AM; Rishi A; Dev S; Bastos JK; Singh M Anticancer Res; 2024 Oct; 44(10):4175-4188. PubMed ID: 39348999 [TBL] [Abstract][Full Text] [Related]
19. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion]. Kang XH; Wang LF; Cao F; Fan FT; Xu ZY Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092 [TBL] [Abstract][Full Text] [Related]
20. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway. Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]